Annual Accounts Receivable
$109.35 M
+$2.44 M+2.28%
31 December 2023
Summary:
Core Laboratories NV annual accounts receivable is currently $109.35 million, with the most recent change of +$2.44 million (+2.28%) on 31 December 2023. During the last 3 years, it has risen by +$26.16 million (+31.45%). CLB annual accounts receivable is now -45.68% below its all-time high of $201.32 million, reached on 31 December 2013.CLB Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$117.59 M
+$1.95 M+1.68%
30 September 2024
Summary:
Core Laboratories NV quarterly accounts receivable is currently $117.59 million, with the most recent change of +$1.95 million (+1.68%) on 30 September 2024. Over the past year, it has increased by +$13.54 million (+13.01%). CLB quarterly accounts receivable is now -43.80% below its all-time high of $209.23 million, reached on 31 March 2014.CLB Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CLB Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +2.3% | +13.0% |
| 3 y3 years | +31.4% | +23.4% |
| 5 y5 years | -15.3% | -14.4% |
CLB Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +31.4% | at high | +23.4% |
| 5 y | 5 years | -16.9% | +31.4% | -14.4% | +41.4% |
| alltime | all time | -45.7% | +31.4% | -43.8% | +41.4% |
Core Laboratories NV Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $117.59 M(+1.7%) |
| June 2024 | - | $115.64 M(+0.5%) |
| Mar 2024 | - | $115.09 M(+5.2%) |
| Dec 2023 | $109.35 M(+2.3%) | $109.35 M(+5.1%) |
| Sept 2023 | - | $104.05 M(-2.6%) |
| June 2023 | - | $106.82 M(-3.5%) |
| Mar 2023 | - | $110.70 M(+3.5%) |
| Dec 2022 | $106.91 M(+10.4%) | $106.91 M(+6.7%) |
| Sept 2022 | - | $100.19 M(+1.0%) |
| June 2022 | - | $99.18 M(+0.3%) |
| Mar 2022 | - | $98.90 M(+2.1%) |
| Dec 2021 | $96.83 M(+16.4%) | $96.83 M(+1.6%) |
| Sept 2021 | - | $95.30 M(+2.2%) |
| June 2021 | - | $93.22 M(+7.7%) |
| Mar 2021 | - | $86.57 M(+4.1%) |
| Dec 2020 | $83.19 M(-36.8%) | $83.19 M(-2.5%) |
| Sept 2020 | - | $85.37 M(-15.9%) |
| June 2020 | - | $101.46 M(-20.0%) |
| Mar 2020 | - | $126.87 M(-3.6%) |
| Dec 2019 | $131.58 M(+1.9%) | $131.58 M(-4.2%) |
| Sept 2019 | - | $137.35 M(+1.8%) |
| June 2019 | - | $134.90 M(+1.5%) |
| Mar 2019 | - | $132.86 M(+2.9%) |
| Dec 2018 | $129.16 M(-3.0%) | $129.16 M(-9.9%) |
| Sept 2018 | - | $143.32 M(+5.3%) |
| June 2018 | - | $136.15 M(-1.1%) |
| Mar 2018 | - | $137.66 M(+3.4%) |
| Dec 2017 | $133.10 M(+16.4%) | $133.10 M(+2.7%) |
| Sept 2017 | - | $129.66 M(+0.5%) |
| June 2017 | - | $128.98 M(+5.9%) |
| Mar 2017 | - | $121.81 M(+6.5%) |
| Dec 2016 | $114.33 M(-21.5%) | $114.33 M(+5.4%) |
| Sept 2016 | - | $108.52 M(-2.9%) |
| June 2016 | - | $111.75 M(-8.8%) |
| Mar 2016 | - | $122.50 M(-15.9%) |
| Dec 2015 | $145.69 M(-26.1%) | $145.69 M(-4.4%) |
| Sept 2015 | - | $152.45 M(-1.7%) |
| June 2015 | - | $155.11 M(-2.4%) |
| Mar 2015 | - | $158.86 M(-19.4%) |
| Dec 2014 | $197.16 M(-2.1%) | $197.16 M(-2.3%) |
| Sept 2014 | - | $201.77 M(+0.4%) |
| June 2014 | - | $200.99 M(-3.9%) |
| Mar 2014 | - | $209.23 M(+3.9%) |
| Dec 2013 | $201.32 M(+9.0%) | $201.32 M(-1.9%) |
| Sept 2013 | - | $205.12 M(+7.5%) |
| June 2013 | - | $190.87 M(-4.6%) |
| Mar 2013 | - | $200.14 M(+8.3%) |
| Dec 2012 | $184.77 M | $184.77 M(+2.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2012 | - | $180.40 M(+5.7%) |
| June 2012 | - | $170.71 M(-0.6%) |
| Mar 2012 | - | $171.66 M(+0.5%) |
| Dec 2011 | $170.81 M(+10.4%) | $170.81 M(+8.4%) |
| Sept 2011 | - | $157.59 M(-1.6%) |
| June 2011 | - | $160.21 M(+1.2%) |
| Mar 2011 | - | $158.31 M(+2.3%) |
| Dec 2010 | $154.73 M(+15.7%) | $154.73 M(+9.6%) |
| Sept 2010 | - | $141.11 M(+2.6%) |
| June 2010 | - | $137.56 M(+5.0%) |
| Mar 2010 | - | $130.99 M(-2.1%) |
| Dec 2009 | $133.76 M(-7.3%) | $133.76 M(+13.4%) |
| Sept 2009 | - | $117.98 M(-4.8%) |
| June 2009 | - | $123.95 M(-5.8%) |
| Mar 2009 | - | $131.56 M(-8.8%) |
| Dec 2008 | $144.29 M(+5.1%) | $144.29 M(-4.0%) |
| Sept 2008 | - | $150.26 M(+0.7%) |
| June 2008 | - | $149.14 M(+1.6%) |
| Mar 2008 | - | $146.74 M(+6.9%) |
| Dec 2007 | $137.23 M(+22.5%) | $137.23 M(-1.2%) |
| Sept 2007 | - | $138.88 M(+7.9%) |
| June 2007 | - | $128.68 M(+4.8%) |
| Mar 2007 | - | $122.84 M(+9.6%) |
| Dec 2006 | $112.06 M(+13.0%) | $112.06 M(+0.9%) |
| Sept 2006 | - | $111.06 M(+4.3%) |
| June 2006 | - | $106.52 M(-2.2%) |
| Mar 2006 | - | $108.88 M(+9.8%) |
| Dec 2005 | $99.13 M(+3.9%) | $99.13 M(+1.5%) |
| Sept 2005 | - | $97.66 M(+1.0%) |
| June 2005 | - | $96.73 M(-1.5%) |
| Mar 2005 | - | $98.16 M(+2.8%) |
| Dec 2004 | $95.45 M(+7.0%) | $95.45 M(+2.1%) |
| Sept 2004 | - | $93.46 M(+3.0%) |
| June 2004 | - | $90.74 M(+1.4%) |
| Mar 2004 | - | $89.53 M(+0.4%) |
| Dec 2003 | $89.20 M(-11.3%) | $89.20 M(-14.8%) |
| Sept 2003 | - | $104.64 M(-1.1%) |
| June 2003 | - | $105.82 M(+7.0%) |
| Mar 2003 | - | $98.90 M(-1.7%) |
| Dec 2002 | $100.60 M(-4.1%) | $100.60 M(+9.1%) |
| Sept 2002 | - | $92.19 M(+4.7%) |
| June 2002 | - | $88.03 M(-8.2%) |
| Mar 2002 | - | $95.91 M(-8.6%) |
| Dec 2001 | $104.93 M(-7.3%) | $104.93 M(-7.6%) |
| Sept 2001 | - | $113.51 M(+5.0%) |
| June 2001 | - | $108.08 M(+2.6%) |
| Mar 2001 | - | $105.34 M(-7.0%) |
| Dec 2000 | $113.21 M | $113.21 M |
FAQ
- What is Core Laboratories NV annual accounts receivable?
- What is the all time high annual accounts receivable for Core Laboratories NV?
- What is Core Laboratories NV annual accounts receivable year-on-year change?
- What is Core Laboratories NV quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Core Laboratories NV?
- What is Core Laboratories NV quarterly accounts receivable year-on-year change?
What is Core Laboratories NV annual accounts receivable?
The current annual accounts receivable of CLB is $109.35 M
What is the all time high annual accounts receivable for Core Laboratories NV?
Core Laboratories NV all-time high annual accounts receivable is $201.32 M
What is Core Laboratories NV annual accounts receivable year-on-year change?
Over the past year, CLB annual accounts receivable has changed by +$2.44 M (+2.28%)
What is Core Laboratories NV quarterly accounts receivable?
The current quarterly accounts receivable of CLB is $117.59 M
What is the all time high quarterly accounts receivable for Core Laboratories NV?
Core Laboratories NV all-time high quarterly accounts receivable is $209.23 M
What is Core Laboratories NV quarterly accounts receivable year-on-year change?
Over the past year, CLB quarterly accounts receivable has changed by +$13.54 M (+13.01%)